The Spring 2024 Biology Seminar Series continues with a talk from Dr. Marice Alcantara, "Investigating Novel Immunotherapies in Renal Cell Carcinoma."
Renal cell carcinoma (RCC) is the most common type of kidney cancer. Despite significant clinical achievement in treating RCC especially using Immune checkpoint blockade (ICB), the response rates remain limited especially in metastatic disease. To better understand immune alterations associated with ICB resistance, my work has focused on assessing blood biomarkers in renal cancer patients classified as responders or non-responders to first line immunotherapy. Using this information, my work has then focused on investigating new combinations of therapy, with the aim to increase and improve responses in patients with RCC.
